New research findings have shown the exceptional sensitivity and specificity of Caris Life Sciences®' Caris Detect, indicating the superiority of Whole Genome Sequencing over methylation-based methods. This breakthrough was reported in Irving, Texas on February 26, 2026. Caris Life Sciences®, listed on NASDAQ as CAI, is a prominent player in providing patient-centered services.